Skip to main content
Download PDF

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

BMC Urology volume 18, Article number: 84 (2018) Cite this article

The Original Article was published on 06 September 2018

Correction to Schultz et al. BMC Urology (2018) 18:77 DOI: 10.1186/s12894-018-0387-7

It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.

Incorrect:

The NNT for rPFS at 2 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Correct:

The NNT for rPFS at 1 year was 2.6 (upper, lower limits: 1.9, 4.0) and at 2 years was 3.0 (1.9, 7.2) when comparing enzalutamide and bicalutamide.

Reference

  1. Schultz NM, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018;18:77.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Astellas Pharma, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA

    Neil M Schultz, Bruce A Brown & Scott C Flanders

  2. Carolina Urologic Research Center, Myrtle Beach, SC, USA

    Neal D Shore

  3. Guy’s, King’s, and St. Thomas’ Hospitals, London, UK

    Simon Chowdhury

  4. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Laurence H Klotz

  5. Urology Associates, P.C, Nashville, TN, USA

    Raoul S Concepcion

  6. Vanderbilt University Medical Center, Nashville, TN, USA

    David F Penson

  7. The Urology Center of Colorado, Denver, CO, USA

    Lawrence I Karsh

  8. Analysis Group, Inc., Boston, MA, USA

    Hongbo Yang

  9. Medivation, Inc., San Francisco, CA, USA

    Arie Barlev

  10. Pfizer, Inc., New York, NY, USA

    Arie Barlev

Authors
  1. Neil M Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal D Shore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simon Chowdhury
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurence H Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Raoul S Concepcion
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David F Penson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lawrence I Karsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hongbo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bruce A Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Arie Barlev
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Scott C Flanders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil M Schultz.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schultz, N.M., Shore, N.D., Chowdhury, S. et al. Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol 18, 84 (2018). https://doi.org/10.1186/s12894-018-0397-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12894-018-0397-5

BMC Urology

ISSN: 1471-2490

Contact us